tiprankstipranks
Trending News
More News >
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
US Market

scPharmaceuticals (SCPH) Stock Forecast & Price Target

Compare
496 Followers
See the Price Targets and Ratings of:

SCPH Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
scPharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SCPH Stock 12 Month Forecast

Average Price Target

$15.60
▲(305.19%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for scPharmaceuticals in the last 3 months. The average price target is $15.60 with a high forecast of $25.00 and a low forecast of $11.00. The average price target represents a 305.19% change from the last price of $3.85.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.53,4.258461538461538,5.986923076923077,7.715384615384615,9.443846153846152,11.17230769230769,12.90076923076923,14.629230769230768,16.357692307692307,18.086153846153845,19.814615384615383,21.54307692307692,23.271538461538462,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.53,3.535384615384615,4.5407692307692304,5.546153846153846,6.5515384615384615,7.556923076923077,8.56230769230769,9.567692307692306,10.573076923076922,11.578461538461537,12.583846153846153,13.589230769230769,14.594615384615382,{"y":15.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.53,3.1815384615384614,3.833076923076923,4.484615384615385,5.136153846153846,5.787692307692308,6.43923076923077,7.090769230769231,7.742307692307692,8.393846153846154,9.045384615384616,9.696923076923078,10.348461538461539,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.12,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.54,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$15.60Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on SCPH
TipRanks AITipRanks
Not Ranked
TipRanks
$4
Hold
3.90%
Upside
Reiterated
06/05/25
scPharmaceuticals' stock score is primarily influenced by its challenging financial position, with high debt levels and negative cash flows. While technical indicators suggest strong momentum, the potential near-term pullback due to overbought conditions and the negative valuation metrics indicate caution. The earnings call provided positive insights, but its impact is not included in the weighted score.
Maxim Group Analyst forecast on SCPH
Naz RahmanMaxim Group
Maxim Group
$12
Buy
211.69%
Upside
Reiterated
05/20/25
Maxim Group Keeps Their Buy Rating on scPharmaceuticals (SCPH)
H.C. Wainwright Analyst forecast on SCPH
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$18
Buy
367.53%
Upside
Reiterated
05/15/25
Analysts' Top Healthcare Picks: PDS Biotechnology (PDSB), scPharmaceuticals (SCPH)
Craig-Hallum
$12
Buy
211.69%
Upside
Reiterated
05/15/25
Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
Leerink Partners Analyst forecast on SCPH
Roanna RuizLeerink Partners
Leerink Partners
$11
Buy
185.71%
Upside
Reiterated
05/15/25
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (NASDAQ: SCPH), 10x Genomics (NASDAQ: TXG) and Kura Oncology (NASDAQ: KURA)
TD Cowen Analyst forecast on SCPH
Stacy KuTD Cowen
TD Cowen
$25
Buy
549.35%
Upside
Reiterated
05/14/25
Promising Growth Outlook for scPharmaceuticals Driven by Furoscix Expansion and Strong Market Demand
Jefferies
$16$13
Buy
237.66%
Upside
Reiterated
12/02/24
scPharmaceuticals (SCPH) PT Lowered to $13 at JefferiesJefferies analyst Glen Santangelo lowered the price target on scPharmaceuticals (NASDAQ: SCPH) to $13.00 (from $16.00) while maintaining a Buy rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on SCPH
TipRanks AITipRanks
Not Ranked
TipRanks
$4
Hold
3.90%
Upside
Reiterated
06/05/25
scPharmaceuticals' stock score is primarily influenced by its challenging financial position, with high debt levels and negative cash flows. While technical indicators suggest strong momentum, the potential near-term pullback due to overbought conditions and the negative valuation metrics indicate caution. The earnings call provided positive insights, but its impact is not included in the weighted score.
Maxim Group Analyst forecast on SCPH
Naz RahmanMaxim Group
Maxim Group
$12
Buy
211.69%
Upside
Reiterated
05/20/25
Maxim Group Keeps Their Buy Rating on scPharmaceuticals (SCPH)
H.C. Wainwright Analyst forecast on SCPH
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$18
Buy
367.53%
Upside
Reiterated
05/15/25
Analysts' Top Healthcare Picks: PDS Biotechnology (PDSB), scPharmaceuticals (SCPH)
Craig-Hallum
$12
Buy
211.69%
Upside
Reiterated
05/15/25
Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
Leerink Partners Analyst forecast on SCPH
Roanna RuizLeerink Partners
Leerink Partners
$11
Buy
185.71%
Upside
Reiterated
05/15/25
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (NASDAQ: SCPH), 10x Genomics (NASDAQ: TXG) and Kura Oncology (NASDAQ: KURA)
TD Cowen Analyst forecast on SCPH
Stacy KuTD Cowen
TD Cowen
$25
Buy
549.35%
Upside
Reiterated
05/14/25
Promising Growth Outlook for scPharmaceuticals Driven by Furoscix Expansion and Strong Market Demand
Jefferies
$16$13
Buy
237.66%
Upside
Reiterated
12/02/24
scPharmaceuticals (SCPH) PT Lowered to $13 at JefferiesJefferies analyst Glen Santangelo lowered the price target on scPharmaceuticals (NASDAQ: SCPH) to $13.00 (from $16.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering scPharmaceuticals

1 Month
xxx
Success Rate
9/19 ratings generated profit
47%
Average Return
+1.79%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.37% of your transactions generating a profit, with an average return of +1.79% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
58%
Average Return
+2.72%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +2.72% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
8/19 ratings generated profit
42%
Average Return
-0.62%
reiterated a buy rating 23 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of -0.62% per trade.
2 Years
xxx
Success Rate
5/15 ratings generated profit
33%
Average Return
-6.33%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -6.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SCPH Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Mar 25
Apr 25
May 25
Strong Buy
10
9
11
10
13
Buy
2
2
6
5
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
11
17
15
18
In the current month, SCPH has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SCPH average Analyst price target in the past 3 months is 15.60.
Each month's total comprises the sum of three months' worth of ratings.

SCPH Financial Forecast

SCPH Earnings Forecast

Next quarter’s earnings estimate for SCPH is -$0.30 with a range of -$0.37 to -$0.25. The previous quarter’s EPS was -$0.37. SCPH beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year SCPH has Outperformed its overall industry.
Next quarter’s earnings estimate for SCPH is -$0.30 with a range of -$0.37 to -$0.25. The previous quarter’s EPS was -$0.37. SCPH beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year SCPH has Outperformed its overall industry.

SCPH Sales Forecast

Next quarter’s sales forecast for SCPH is $15.41M with a range of $14.47M to $17.70M. The previous quarter’s sales results were $11.75M. SCPH beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 70.18% of the time in the same period. In the last calendar year SCPH has Outperformed its overall industry.
Next quarter’s sales forecast for SCPH is $15.41M with a range of $14.47M to $17.70M. The previous quarter’s sales results were $11.75M. SCPH beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 70.18% of the time in the same period. In the last calendar year SCPH has Outperformed its overall industry.

SCPH Stock Forecast FAQ

What is SCPH’s average 12-month price target, according to analysts?
Based on analyst ratings, scPharmaceuticals Inc’s 12-month average price target is 15.60.
    What is SCPH’s upside potential, based on the analysts’ average price target?
    scPharmaceuticals Inc has 305.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SCPH a Buy, Sell or Hold?
          scPharmaceuticals Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is scPharmaceuticals Inc’s price target?
            The average price target for scPharmaceuticals Inc is 15.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $11.00. The average price target represents 305.19% Increase from the current price of $3.85.
              What do analysts say about scPharmaceuticals Inc?
              scPharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of SCPH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis